Histological benefits of virological response to peginterferon alfa-2a monotherapy in patients with hepatitis C and advanced fibrosis or compensated cirrhosis

Alimentary Pharmacology and Therapeutics

Volumn 27, Issue 7, 2008, Pages 542-551

  Everson, G T ^a,b   Balart, L ^c   Lee, S S ^d   Reindollar, R W ^e   Shiffman, M L ^f   Minuk, G Y ^g   Pockros, P J ^h   Govindarajan, S ⁱ   Lentz, E ^j   Heathcote, E J ^k  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^d UNIVERSITY OF CALGARY   (Canada)

^e Carolinas Center for Liver Disease   (United States)

^f VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

^g UNIVERSITY OF MANITOBA   (Canada)

^h SCRIPPS CLINIC   (United States)

ⁱ UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^j HOFFMANN LA ROCHE INC   (United States)

^k TORONTO WESTERN HOSPITAL   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; PEGINTERFERON ALPHA2A;

ADULT; ARTICLE; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; FEMALE; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE REGRESSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SINGLE BLIND PROCEDURE; TREATMENT RESPONSE; VIROLOGY;

ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON ALFA-2A; LIVER CIRRHOSIS; LOGISTIC MODELS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; TREATMENT OUTCOME;

EID: 39849091806     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2008.03620.x     Document Type: Article

References (40)

1. Ryder SD, Irving WL, Jones DA, et al. Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut 2004 53: 451 5.
2. Strader DB, Wright T, Thomas DL, et al. American Association for the Study of Liver Diseases practice guideline: diagnosis, management, and treatment of hepatitis C. Hepatology 2004 39: 1147 71.
3. Shiratori Y, Imazeki F, Moriyama M, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000 132: 517 24.
4. Alric L, Duffaut M, Selves J, et al. Maintenance therapy with gradual reduction of the interferon dose over one year improves histological response in patients with chronic hepatitis C with biochemical response: results of a randomized trial. J Hepatol 2001 35: 272 8.
5. Arif A, Levine RA, Sanderson SO, et al. Regression of fibrosis in chronic hepatitis C after therapy with interferon and ribavirin. Dig Dis Sci 2003 48: 1425 30.
6. Pockros PJ, Carithers R, Desmond P, et al., for the PEGASYS® International Study Group. Efficacy and safety of two-dose regimens of peginterferon alfa-2a compared with interferon alfa-2a in chronic hepatitis C: a multicenter, randomized controlled trial. Am J Gastroenterol 2004 99: 1298 305.
7. Poynard T, McHutchison J, Manns M, et al., for the PEG-FIBROSIS Project Group. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002 122: 1303 13.
8. Cammà C, Di Bona D, Schepis F, et al. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. Hepatology 2004 39: 333 42.
9. Everson GT. Treatment of chronic hepatitis C in patients with decompensated cirrhosis. Rev Gastroenterol Disord 2004 4 (Suppl. 1 S31 8.
10. Sobesky R, Mathurin P, Charlotte F, et al., for the Multivirc Group. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. Gastroenterology 1999 116: 378 86.
11. Rubbia-Brandt L, Fabris P, Paganin S, et al. Steatosis affects chronic hepatitis C progression in a genotype specific way. Gut 2004 53: 406 12.
12. Ratziu V, Trabut J-B, Poynard T. Fat, diabetes, and liver injury in chronic hepatitis C. Curr Gastroenterol Rep 2004 6: 22 9.
13. Ortiz V, Berenguer M, Rayón JM, et al. Contribution of obesity to hepatitis C-related fibrosis progression. Am J Gastroenterol 2002 97: 2408 14.
14. McCaughan GW, George J. Fibrosis progression in chronic hepatitis C virus infection. Gut 2004 53: 318 21.
15. Hui JM, Sud A, Farrell GC, et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Gastroenterology 2003 125: 1695 704.
16. Myers RP, Hilsden RJ, Lee SS. Historical features are poor predictors of liver fibrosis in Canadian patients with chronic hepatitis C. J Viral Hepat 2001 8: 249 55.
17. Wiley TE, Brown J, Chan J. Hepatitis C infection in African Americans: its natural history and histological progression. Am J Gastroenterol 2002 97: 700 6.
18. Reddy KR, Hoofnagle JH, Tong MJ, et al., for the Consensus Interferon Study Group. Racial differences in responses to therapy with interferon in chronic hepatitis C. Hepatology 1999 30: 787 93.
19. Asselah T, Rubbia-Brandt L, Marcellin P, et al. Steatosis in chronic hepatitis C: why does it really matter? Gut 2006 55: 123 30.
20. Leandro G, Mangia A, Hui J, et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006 130: 1636 42.
21. Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann Intern Med 2004 140: 370 81.
22. Heathcote EJ, Shiffman ML, Cooksley WGE, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000 343: 1673 80.
23. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981 1: 431 5.
24. Bedossa P, Poynard T, for the METAVIR Cooperative Study Group. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 1996 24: 289 93.
25. Germer JJ, Rys PN, Thorvilson JN, et al. Determination of hepatitis C virus genotype by direct sequence analysis of products generated with the Amplicor HCV test. J Clin Microbiol 1999 37: 2625 30.
26. Shiffman ML, Hofmann CM, Contos MJ, et al. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology 1999 117: 1164 72.
27. Ferenci P, Fried MW, Shiffman ML, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005 43: 425 33.
28. Layden TJ, Layden JE, Reddy KR, et al. Induction therapy with consensus interferon (CIFN) does not improve sustained virologic response in chronic hepatitis C. J Viral Hepat 2002 9: 334 9.
29. Fontana RJ, Everson GT, Tuteja S, et al. Controversies in the management of hepatitis C patients with advanced fibrosis and cirrhosis. Clin Gastroenterol Hepatol 2004 2: 183 97.
30. Bruno S, Stroffolini T, Colombo M, et al. Sustained virological response to interferon-alfa is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007 45: 579 87.
31. Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007 147: 677 84.
32. Arase Y, Ikeda K, Suzuki F, et al. Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection. J Med Virol 2007 79: 1485 90.
33. Arase Y, Ikeda K, Suzuki F, et al. Prolonged-interferon therapy reduces hepatocarcinogenesis in aged-patients with chronic hepatitis C. J Med Virol 2007 79: 1095 102.
34. Rincon D, Ripoll C, Lo Iacono O, et al. Antiviral therapy decreases hepatic venous pressure gradient in patients with chronic hepatitis C and advanced fibrosis. Am J Gastroenterol 2006 101: 2269 74.
35. Huang JF, Yu ML, Lee CM, et al. Sustained virological response to interferon reduces cirrhosis in chronic hepatitis C: a 1,386-patient study from Taiwan. Aliment Pharmacol Ther 2007 25: 1029 37.
36. Fartoux L, Degos F, Trepo C, et al. Effect of prolonged interferon therapy on the outcome of hepatitis C virus-related cirrhosis: a randomized trial. Clin Gastroenterol Hepatol 2007 5: 502 7.
37. Di Bisceglie AM, Shiffman ML, Everson GT, et al. Prolonged antiviral therapy with peginterferon to prevent complications of advanced liver disease associated with hepatitis C: results of the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) trial. Hepatology 2007 46: 290A (abstract LB1).
38. Mallat A, Preaux AM, Blazejewski S, et al. Interferon alfa and gamma inhibit proliferation and collagen synthesis of human Ito cells in culture. Hepatology 1995 21: 1003 10.
39. Knittel T, Muller L, Saile B, et al. Effect of tumour necrosis factor-alfa on proliferation, activation and protein synthesis of rat hepatic stellate cells. J Hepatol 1997 27: 1067 80.
40. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000 343: 1666 72.